Trial Profile
A Randomized, Double-Blind, Placebo-Controlled Study of Liposomal Amikacin for Inhalation in Patients With Recalcitrant Nontuberculous Mycobacterial Lung Disease
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Amikacin (Primary)
- Indications Mycobacterium avium complex infections; Nontuberculous mycobacterium infections; Respiratory tract infections
- Focus Therapeutic Use
- Acronyms TARGET-NTM
- Sponsors Insmed
- 19 May 2021 According to an Insmed media release, data from this trial will be presented at he virtual American Thoracic Society (ATS) 2021 International Conference.
- 17 Feb 2021 Results (n=53) of pooled analysis of TR02-112 and CONVERT trials, assessing the pharmacokinetic properties of once-daily amikacin liposome inhalation suspension in patients with treatment-refractory NTM lung disease, published in the European Journal of Drug Metabolism and Pharmacokinetics
- 01 Apr 2019 According to an Insmed media release, results of pooled pharmacokinetic analysis from this and a phase III study (CONVERT) will be presented at the American Thoracic Society (ATS) International Conference in May 2019.